Sugi Predict

Sugi Predict / Compounds / SCHEMBL21069438

SCHEMBL21069438

SCHEMBL21069438

COC(=O)c1ccc(-n2cc(N)c(C(F)F)n2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGS1 P23219 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ HTT P42858 2/20 0.41
▸ MAPT P10636 5/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ HSD17B10 Q99714 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ TP53 P04637 1/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ SMN1; SMN2 Q16637 1/20 0.40
▸ MAPKAPK2 P49137 1/20 0.39
▸ HPGD P15428 3/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ ATM Q13315 1/20 0.39
▸ TDP1 Q9NUW8 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21069305 0.85 KCNJ1 (0.44) ALDH1A1HTTMAPTNPC1RAB9A
SCHEMBL21070025 0.84 HSD17B10 (0.42) PTGS1ALDH1A1HTTMAPTKDM4E
SCHEMBL23946141 0.83 ALDH1A1 (0.40) PTGS1ALDH1A1HTTMAPTKDM4E
SCHEMBL21070176 0.83 MAPK1 (0.43) ALDH1A1MAPTKDM4EHSD17B10NPC1
SCHEMBL21070541 0.82 CA12 (0.40) ALDH1A1MAPTKDM4EHSD17B10NPC1
SCHEMBL21997660 0.80 SMN1; SMN2 (0.44) ALDH1A1HTTMAPTKDM4EHSD17B10
SCHEMBL21070794 0.79 DGAT1 (0.46) PTGS1ALDH1A1HTTMAPTKDM4E
SCHEMBL21069598 0.78 MAPT (0.44) PTGS1ALDH1A1HTTMAPTKDM4E
SCHEMBL6468659 0.78 ALDH1A1 (0.47) PTGS1ALDH1A1HTTMAPTKDM4E
Ammonia Solution, Strong SCHEMBL21070052 0.77 ALDH1A1 (0.46) PTGS1ALDH1A1HTTMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 — — EP disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-05-22 — — US disclosed
US-12258341-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2025-03-25 — — US disclosed
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-09 — — US disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
EP-4472967-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2024-12-11 — — EP disclosed
CN-113423427-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2021-09-21 — — CN disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
CN-112105385-A IRAK degrading agents and uses thereof 凯麦拉医疗公司 2020-12-18 — — CN disclosed
EP-3731869-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2020-11-04 — — EP disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-12258341-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-20250163042-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-20250011325-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 PTGS1 3012/4885ALDH1A1 2776/4885HTT 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.